Why the study?
Does a low dose of spironolactone added to standard treatment reduce the risk of death in patients with current or recent heart failure?
Does a low dose of spironolactone added to standard treatment reduce the risk of death in patients with current or recent heart failure?
Answers are grounded in this paper and cite their sources.
This editorial discusses the real-world application and implications of the RALES trial findings, which demonstrated a 30% reduction in mortality with spironolactone in heart failure patients.
The application of evidence based on the results of clinical trials is a key aim of modern medical practice. Viewed from that perspective, the findings of Juurlink and colleagues in this issue of the Journal (pages 543–551) could be considered encouraging. The Randomized Aldactone Evaluation Study (RALES) showed that, when added to standard treatment (including an angiotensin-converting–enzyme [ACE] inhibitor), a low dose of the aldosterone antagonist spironolactone reduced the risk of death by 30 percent over an average follow-up period of two years among carefully selected patients with current or recent heart failure of New York Heart Association (NYHA) functional . . .
No takes yet. Share an insight, caveat, or question.
McMurray et al. (2004) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: